Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy

Puntos clave

• Outcomes indicate a notable response rate in patients with relapsed mantle cell lymphoma, highlighting its efficacy.
• In a compassionate use program, 25% of patients achieved a complete response, reflecting significant therapeutic potential.
• Assessment of real-world data from the compassionate use program showed positive results for treatment efficacy.
• Findings may inform future treatment guidelines, especially for relapsed or refractory cases of mantle cell lymphoma.

Resumen